



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

John R. HESS *et al.*

Appl. No. 09/756,907

Filed: January 10, 2001

For: COMPOSITIONS FOR  
TREATMENT OF  
HEMORRHAGING WITH  
ACTIVATED FACTOR VLLA IN  
COMBINATION WITH  
FIBRINOGEN AND METHODS  
OF USING SAME

Art Unit: 3614

Examiner: n/a

Atty. Docket No. 38644-170537

Customer No. 6339



26694

PATENT TRADEMARK OFFICE

RECEIVED  
SEP 19 2002  
CENTER 1600/2900

RECEIVED

SEP 17 2002

GROUP 3600

SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

This is a Supplemental Information Disclosure Statement submitted under 37 C.F.R.  
§ 1.97 within the time specified under 37 C.F.R. § 1.97(b).


In order to comply with applicant's duty of disclosure under 37 C.F.R. § 1.56, the U.S.  
Patent and Trademark Office is notified of the documents which are listed on the attached Form  
PTO-1449 and which the Examiner may deem relevant to patentability of the claims of the  
above-identified application. One copy of each of the listed documents is submitted herewith.

The present Supplemental Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no Statement Under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In view of the above, no further translation or statement of relevance is required, and as all requirements of 37 C.F.R. § 1.97 and all official guide lines pertaining to Information Disclosure Statements have been complied with, and it is therefore respectfully requested that the Examiner consider the documents and make them of record.

Please charge any necessary fee or credit any overpayment in connection with this Information Disclosure Statement to Deposit Account No. 22-0261.

Respectfully submitted,



Thomas G. Wiseman  
Registration No. 35,046

Date: September 16, 2002

VENABLE  
P.O. Box 34385  
Washington, D.C. 20043-9998  
Telephone: (202) 962-4800  
Telex: (202) 962-8300

+

+

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

(use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Application Number	09/756,907
Filing Date	January 10, 2001
First Named Inventor	John R. HESS et al.
Group Art Unit	3614
Examiner Name	n/a
Attorney Docket Number	38644-170537

[illegible]

RECEIVED

RECEIVED

SEP 17 2002

**GROUP 3600**

[illegible]

**Examiner  
Signature**

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

VENABLE